Patents by Inventor May Han

May Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Surface finishes with low RBTV for fine and mixed bump pitch architectures
    Patent number: 11935857
    Abstract: Embodiments described herein include electronic packages and methods of forming such packages. An electronic package includes a package substrate, first conductive pads formed over the package substrate, where the first conductive pads have a first surface area, and second conductive pads over the package substrate, where the second conductive pads have a second surface area greater than the first surface area. The electronic package also includes a solder resist layer over the first and second conductive pads, and a plurality of solder resist openings that expose one of the first or second conductive pads. The solder resist openings of the electronic package may include conductive material that is substantially coplanar with a top surface of the solder resist layer. The electronic package further includes solder bumps over the conductive material in the solder resist openings, where the solder bumps have a low bump thickness variation (BTV).
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: March 19, 2024
    Assignee: Intel Corporation
    Inventors: Kristof Darmawaikarta, Robert May, Sashi Kandanur, Sri Ranga Sai Boyapati, Srinivas Pietambaram, Steve Cho, Jung Kyu Han, Thomas Heaton, Ali Lehaf, Ravindranadh Eluri, Hiroki Tanaka, Aleksandar Aleksov, Dilan Seneviratne
  • Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
    Publication number: 20150285817
    Abstract: A test to identify whether a lung patient is likely to benefit from combination therapy in the form of an epidermal growth factor receptor inhibitor (EGFR-I) and a monoclonal antibody drug targeting hepatocyte growth factor (HGF) as compared to EGFR-I monotherapy. The test makes use of a mass spectrum obtained from a serum or plasma sample and a computer configured as a classifier operating on the mass spectrum and a training set in the form of class-labeled mass spectra from other cancer patients. The computer classifier executes a classification algorithm, such as K-nearest neighbor, and assigns a class label to the serum or plasma sample. Samples classified as “Poor” or the equivalent are associated with patients which are likely to benefit from the combination therapy more than from EGFR-I monotherapy. The invention also includes improved methods of treating patients predicted by the test.
    Type: Application
    Filed: April 3, 2015
    Publication date: October 8, 2015
    Inventors: Heinrich Röder, Julia Grigorieva, May Han, Philip Komarnitsky, Jeno Gyuris
  • Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins
    Patent number: 9096664
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: August 4, 2015
    Assignees: AVEO Pharmaceuticals, Inc., Xoma Technologies, Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Anti-ron antibodies
    Patent number: 8829164
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 9, 2014
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20140178935
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: October 2, 2013
    Publication date: June 26, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20140178934
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: September 27, 2013
    Publication date: June 26, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • ANTI-RON ANTIBODIES
    Publication number: 20140066603
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Application
    Filed: November 1, 2013
    Publication date: March 6, 2014
    Applicant: AVEO PHARMACEUTICALS, INC.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • Anti-RON antibodies
    Patent number: 8603478
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: December 10, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8580930
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: November 12, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8575318
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: November 5, 2013
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20130203963
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS
    Publication number: 20130203970
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 8273355
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 25, 2012
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • ()
    Patent number: 8268315
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 18, 2012
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • ANTI-RON ANTIBODIES
    Publication number: 20120027773
    Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
    Type: Application
    Filed: July 6, 2011
    Publication date: February 2, 2012
    Inventors: Kerry Whalen, Steve Botega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, JR., Jeno Gyuris
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20110236377
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 29, 2011
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20110229462
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 22, 2011
    Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7943344
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 17, 2011
    Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • Hepatocyte growth factor (HGF) binding proteins
    Patent number: 7935502
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 3, 2011
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
  • Hepatocyte Growth Factor (HGF) Binding Proteins
    Publication number: 20100173361
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Application
    Filed: December 7, 2009
    Publication date: July 8, 2010
    Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris